Regenxbio Inc - ESG Rating & Company Profile powered by AI
Check the bottom of the page for potential risks for Regenxbio Inc based on sector, location and size. If you are employed by Regenxbio Inc and you would like to use your Sustainability rating, please contact us. Other corporations in the rating peer group for Regenxbio Inc are displayed below.
Regenxbio Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.4; made up of an environmental score of 4.0, social score of 1.6 and governance score of 1.6.
2.4
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1499 | Verici Dx Plc | 2.5 | Medium |
| 1499 | Verve Therapeutics Inc | 2.5 | Medium |
| 1512 | Regenxbio Inc | 2.4 | Medium |
| 1512 | CEL-SCI Corp | 2.4 | Medium |
| 1512 | Allena Pharmaceuticals Inc | 2.4 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Regenxbio Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Regenxbio Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Regenxbio Inc report the average age of the workforce?
Sign up for free to unlockDoes Regenxbio Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Regenxbio Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Regenxbio Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Regenxbio Inc offer flexible work?
Sign up for free to unlockDoes Regenxbio Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Regenxbio Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Regenxbio Inc conduct supply chain audits?
Sign up for free to unlockDoes Regenxbio Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Regenxbio Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Regenxbio Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Regenxbio Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Regenxbio Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Regenxbio Inc disclose water use targets?
Sign up for free to unlockDoes Regenxbio Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Regenxbio Inc have a product recall in the last two years?
Sign up for free to unlockDoes Regenxbio Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Regenxbio Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Regenxbio Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Regenxbio Inc disclose parental leave metrics?
Sign up for free to unlockDoes Regenxbio Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Regenxbio Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Regenxbio Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Regenxbio Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Regenxbio Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Regenxbio Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Regenxbio Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Regenxbio Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Regenxbio Inc disclose its waste policy?
Sign up for free to unlockDoes Regenxbio Inc report according to TCFD requirements?
Sign up for free to unlockDoes Regenxbio Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Regenxbio Inc disclose energy use targets?
Sign up for free to unlockDoes Regenxbio Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Regenxbio Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Regenxbio Inc
These potential risks are based on the size, segment and geographies of the company.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.